Alimta data boosts survival prospects of lung cancer patients
Ahead of the American Society of Clinical Oncology meeting in Chicago at the end of month, Eli Lilly has presented data showing that treatment with the firm’s Alimta given as a maintenance therapy after chemotherapy increases the survival prospects of patients with advanced non-small cell lung cancer.
This entry was posted on Monday, May 19th, 2008 at 9:55 am and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.